Myo-Inositol and Rosuvastatin Interaction: What Women with PCOS and High Cholesterol Need to Know

The Short Answer on Safety

Taking myo-inositol (especially the myo-inositol plus D-chiro-inositol combination) alongside rosuvastatin does not trigger a clinically significant pharmacokinetic drug-drug interaction based on current mechanistic data. Rosuvastatin is a substrate of the OATP1B1 and OATP1B3 hepatic uptake transporters as well as BCRP efflux, and its metabolism involves only minor CYP2C9 involvement. Myo-inositol is a naturally occurring polyol that the body synthesizes from glucose; it is not a known inducer or inhibitor of CYP2C9, CYP3A4, P-glycoprotein, or OATP transporters, so it is unlikely to alter rosuvastatin's plasma exposure in a meaningful way.

"no direct drug interaction" is not the same as "no clinical considerations." Women taking both agents deserve a clearer picture.

Why This Combination Comes Up

The overlap is not random. PCOS affects roughly 8 to 13 percent of women of reproductive age worldwide and brings with it insulin resistance, anovulation, and a lipid profile that frequently includes elevated triglycerides, low HDL-C, and small dense LDL particles. Myo-inositol is one of the most commonly purchased supplements for PCOS management. Rosuvastatin is among the most prescribed statins globally, with statin prescribing in women rising sharply after the 2013 ACC/AHA cholesterol guidelines expanded the treatment-eligible population.

A woman with PCOS who is also dealing with dyslipidemia, often worsened by hyperinsulinemia, is exactly the patient who might reach for both.

Who Typically Takes This Combination by Life Stage

Reproductive years (20s to early 40s): The most common scenario. A woman in her 30s manages PCOS-related anovulation with myo-inositol and then receives rosuvastatin for a cardiovascular risk factor, familial hypercholesterolemia, or persistently elevated LDL despite lifestyle changes.

Perimenopause (roughly ages 45 to 52): Estrogen decline accelerates LDL-C rise, and some women who managed PCOS insulin resistance without medication for years now find their metabolic markers worsening. Statin initiation in this window is common, and some continue inositol supplementation for metabolic or mood support.

Post-menopause: Rosuvastatin use is higher; myo-inositol use for fertility and cycle regulation is much less common, though some women continue it for insulin sensitivity or mood.

How Rosuvastatin Works (and Where Interaction Risk Lives)

Rosuvastatin is a selective HMG-CoA reductase inhibitor. It reduces hepatic cholesterol synthesis, which up-regulates LDL receptors and clears LDL particles from the blood. Unlike many statins, rosuvastatin undergoes minimal hepatic CYP metabolism, with CYP2C9 responsible for only about 10 percent of its biotransformation. The main pharmacokinetic chokepoints are the OATP1B1 and OATP1B3 transporters that move rosuvastatin into hepatocytes, and the BCRP efflux transporter.

Drugs that inhibit OATP1B1 (cyclosporine, gemfibrozil, lopinavir/ritonavir) dramatically increase rosuvastatin exposure and myopathy risk. Myo-inositol has no known affinity for these transporters. There is no published in vitro or in vivo data, as of early 2025, showing that myo-inositol or D-chiro-inositol inhibits OATP1B1, OATP1B3, BCRP, or CYP2C9.

Sex-Specific Pharmacokinetics of Rosuvastatin

This point matters and is often omitted from general statin guides. Women show approximately 50 percent higher rosuvastatin AUC compared with men in some pharmacokinetic studies, likely reflecting differences in body weight, body composition, and possibly OATP transporter expression. The FDA label for rosuvastatin notes that Asian patients have elevated plasma levels and recommends starting at 5 mg, but a similar dose-conservatism argument applies to smaller women even outside that ethnic category.

Practical consequence: a woman prescribed 20 mg or 40 mg rosuvastatin may already be at the higher end of her effective exposure curve. Anything that further stresses the muscle or liver should be identified, even if myo-inositol is not one of those things.

How Myo-Inositol Works in Women

Myo-inositol is the most abundant inositol stereoisomer in the human body. It acts as a second messenger in the insulin signaling cascade, specifically as a precursor to phosphatidylinositol and inositol phosphoglycans (IPGs) that mediate insulin receptor downstream activity. In PCOS, there is evidence of a defect in the enzyme epimerizing myo-inositol to D-chiro-inositol in peripheral tissue, which may worsen insulin resistance.

The 40:1 ratio of myo-inositol to D-chiro-inositol mirrors the physiologic plasma ratio and has become the most studied formulation. A typical dose is 2 g myo-inositol plus 200 mg D-chiro-inositol twice daily, though doses up to 4 g myo-inositol daily have been used in fertility studies.

Effects on Lipids in PCOS

This is where pharmacodynamic overlap with rosuvastatin becomes relevant. A 2012 randomized trial by Nordio and Proietti showed that the 40:1 myo-inositol/D-chiro-inositol combination reduced fasting insulin, LDL-C, and triglycerides in women with PCOS compared with either isomer alone. A meta-analysis published in Gynecological Endocrinology found that inositol supplementation significantly reduced fasting insulin (mean difference approximately 2.39 mIU/L) and improved HOMA-IR in PCOS.

If myo-inositol independently lowers LDL-C modestly, and rosuvastatin lowers it substantially, the clinical result of the combination could be a lower LDL-C than either party expected. This is not dangerous, but it is worth tracking so that the statin dose is not escalated unnecessarily.

Effects on Ovulation and the Menstrual Cycle

In women trying to conceive, myo-inositol has been shown in several small randomized trials to improve oocyte quality and restore spontaneous ovulation in PCOS. Restored ovulation means restored fertility. If rosuvastatin is prescribed concurrently in a woman who might become pregnant, the teratogenicity concern becomes urgent. See the pregnancy section below.

Pharmacodynamic Considerations: The Real Clinical Overlap

The clinically meaningful interaction here is pharmacodynamic, not pharmacokinetic. Here is a practical framework for thinking through this combination in women:

Lipid effects (additive, likely beneficial): Rosuvastatin lowers LDL-C by 45 to 55 percent at typical doses. Myo-inositol may reduce LDL-C modestly (estimated 5 to 10 percent based on available PCOS trial data). The combination likely achieves better LDL-C reduction than rosuvastatin alone, particularly in a woman with PCOS-driven dyslipidemia where hyperinsulinemia is driving hepatic lipogenesis.

Insulin sensitivity (additive, monitor glucose): Both agents improve insulin sensitivity by different mechanisms. Rosuvastatin has a known, modest adverse effect on glucose metabolism at higher doses, particularly in women who are already insulin-resistant. The JUPITER trial found a 25 percent increased risk of new-onset diabetes with rosuvastatin 20 mg in a population that included post-menopausal women. Myo-inositol works in the opposite direction, improving insulin receptor signaling. Whether myo-inositol attenuates statin-associated dysglycemia in women with PCOS has not been directly studied in a randomized trial, but the mechanistic logic is sound.

Muscle risk (rosuvastatin specific, inositol not implicated): Statin-associated myopathy is dose-dependent and more common at higher exposures. Myo-inositol has no known muscle toxicity and is not a mitochondrial uncoupler. Women at higher muscle risk from rosuvastatin include those with hypothyroidism, those taking CYP2C9 inhibitors like fluconazole, and those with renal impairment. None of these risks are introduced or worsened by myo-inositol.

Statin-Associated Dysglycemia in Women: A Sex-Specific Risk

Women face a disproportionate risk of statin-associated new-onset diabetes compared with men. A 2015 meta-analysis in Diabetologia found that statin use was associated with a 10 percent higher relative risk of new-onset type 2 diabetes in women, with some analyses suggesting higher absolute risk than in men after controlling for baseline glycemia.

For women with PCOS, who already carry elevated baseline diabetes risk, this is particularly relevant. The Endocrine Society's 2023 PCOS clinical practice guideline recommends screening for type 2 diabetes or prediabetes in all women with PCOS at diagnosis, with repeat screening every one to three years.

If you have PCOS and your clinician prescribes rosuvastatin, asking for a baseline HbA1c and fasting glucose before starting, and repeating at six to twelve months, is entirely reasonable. Myo-inositol's insulin-sensitizing action does not eliminate statin-associated dysglycemia risk, but it may buffer it partially.

Life-Stage Dosing and Monitoring Guidance

Reproductive Years (Trying to Conceive)

Stop rosuvastatin before attempting conception. Full stop. Myo-inositol at 2 g twice daily may be continued as it supports ovulation and oocyte quality in PCOS. If cardiovascular risk genuinely requires statin therapy in a woman actively trying to conceive, this is a clinical judgment that requires specialist input and detailed counseling.

Reproductive Years (Not Trying to Conceive)

Use reliable contraception if taking rosuvastatin. Monitor LDL-C at baseline, at 4 to 6 weeks after statin initiation, and then every 6 to 12 months. Add HbA1c and fasting glucose monitoring given the PCOS plus statin dysglycemia risk. Myo-inositol 2 g plus 200 mg D-chiro-inositol twice daily may be continued alongside rosuvastatin without dose adjustment.

Perimenopause

LDL-C often rises as estrogen falls. Rosuvastatin dose may need to be reassessed upward. Myo-inositol may be continued if the woman still derives metabolic benefit. Watch for new or worsening insulin resistance during the menopausal transition, since both the hormonal shift and higher statin doses can contribute.

Post-Menopause

Rosuvastatin is appropriate and well-studied in this group. Myo-inositol use is less evidence-based in post-menopause for metabolic purposes, though some women continue it. No drug interaction concern arises specifically from post-menopausal status.

Pregnancy and Lactation Safety

This section is mandatory reading if you are pregnant, might become pregnant, or are breastfeeding.

Rosuvastatin in Pregnancy

Rosuvastatin is contraindicated in pregnancy. It carries an FDA-designated warning based on animal reproductive toxicity data showing fetal skeletal malformations, and human data are insufficient to establish safety. The FDA label states plainly that rosuvastatin should be discontinued as soon as pregnancy is recognized. Because cholesterol biosynthesis is critical for fetal development, HMG-CoA reductase inhibition during organogenesis is a theoretical teratogenic mechanism with plausible biological grounding.

Any woman of reproductive potential taking rosuvastatin should use effective contraception throughout treatment. If you are taking rosuvastatin and your myo-inositol restores ovulation (which it may do in PCOS), your pregnancy risk increases and contraception becomes more, not less, important.

Myo-Inositol in Pregnancy

Myo-inositol is not contraindicated in pregnancy. A substantial body of data, including the large UK-based randomized controlled trial ISRCTN10366605 published in BJOG, examined myo-inositol supplementation in pregnancy specifically for gestational diabetes prevention. While that trial found no significant reduction in gestational diabetes incidence at the dose studied, it did not find harm. Italian and UK trial data also support the safety profile for fetal outcomes.

Some clinicians use myo-inositol in early pregnancy in women with PCOS specifically for its role in reducing miscarriage risk associated with insulin resistance, though this remains an off-label use with limited high-quality evidence.

Lactation

No published human lactation pharmacokinetic data exist for supplemental myo-inositol at therapeutic doses. Myo-inositol is naturally present in breast milk as a normal constituent, which provides some biological plausibility for safety. Rosuvastatin, by contrast, should not be used during breastfeeding. The FDA label advises against use because statins may interfere with infant lipid metabolism during a period when cholesterol is critical for neurological development.

Who This Combination Is Right For (and Who Should Pause)

Generally Appropriate

• A woman in her 30s with well-documented PCOS taking myo-inositol for ovulation support and rosuvastatin for familial hypercholesterolemia, using reliable contraception
• A perimenopausal woman with PCOS history, now stable metabolically, who needs rosuvastatin for primary cardiovascular prevention and continues inositol for insulin sensitivity
• Any woman where the prescribing clinician has reviewed both agents together and documented a monitoring plan

Requires More Careful Discussion

• A woman with PCOS actively trying to conceive: rosuvastatin must be stopped; myo-inositol may be continued and is often encouraged
• A woman with borderline fasting glucose or prediabetes who now needs rosuvastatin: the statin-dysglycemia risk is elevated, and close glucose monitoring is needed
• A woman already on high-dose rosuvastatin (40 mg) with muscle symptoms: myo-inositol does not worsen myopathy risk, but any new supplement should be disclosed to the prescribing clinician so the full clinical picture is accurate

Not Right For

• Pregnant women: rosuvastatin is contraindicated; myo-inositol may be continued but discuss with your OB or MFM provider
• Breastfeeding women: rosuvastatin should be stopped; myo-inositol data are reassuring but incomplete

Practical Counseling Points for Women

Keep both your prescribing clinician and any specialist managing your PCOS informed that you are taking myo-inositol. Supplements are frequently omitted from medication lists, and the metabolic overlap matters for interpreting your labs.

Your LDL-C may fall more than your clinician expects if myo-inositol is actively improving your insulin-mediated hepatic lipid metabolism. This is a good outcome, not a reason to worry, but it should be noted so statin dose is not over-escalated.

Ask for an HbA1c at baseline if you have PCOS and are starting rosuvastatin. The PCOS-plus-statin diabetes risk combination is real and worth tracking, not assumed away.

If you notice muscle pain, weakness, or dark urine after starting rosuvastatin (with or without myo-inositol), contact your clinician promptly. Report the CPK level and, if elevated more than 10 times the upper limit of normal, rosuvastatin should be held. Myo-inositol does not cause or worsen rhabdomyolysis.

A baseline lipid panel, fasting glucose, and HbA1c before starting the combination, with repeat testing at 3 to 6 months, gives both you and your clinician the data needed to confirm the combination is working as intended.

The Evidence Gap Women Deserve to Know About

No randomized controlled trial has specifically enrolled women with PCOS taking myo-inositol and then randomized them to rosuvastatin versus placebo to observe interaction effects. The conclusions above are built from:

1. Mechanistic pharmacokinetic data on rosuvastatin's transport and metabolism pathways
2. In vitro and in vivo inositol pharmacology showing no CYP or OATP transporter activity
3. Separate trial data on myo-inositol effects in PCOS and on rosuvastatin effects in mixed-sex populations

Women have been systematically underrepresented in statin pharmacokinetic trials. The 2020 JAMA Internal Medicine analysis by Lobo et al. documented that women comprise only about 40 percent of cardiovascular trial participants despite carrying equivalent or higher absolute cardiovascular risk post-menopause. Sex-stratified PK data for rosuvastatin remain sparse. The higher AUC observed in women may reflect real transporter biology that has not been fully characterized.

If you are a clinician advising a patient on this combination, the honest answer is: direct interaction data in women do not exist, mechanistic data are reassuring, but metabolic monitoring is warranted given the pharmacodynamic overlap.